Anti-SCAP / SREBP cleavage-activating protein

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. The SCAP antibody targets SREBP cleavage-activating protein, a key membrane-bound regulator of cholesterol and lipid homeostasis encoded by the SCAP gene. This protein acts as a sterol sensor that governs the trafficking and activation of sterol regulatory element-binding proteins (SREBPs), transcription factors that control lipid biosynthesis. SREBP cleavage-activating protein monitors cellular sterol levels and facilitates the transport of SREBPs from the endoplasmic reticulum (ER) to the Golgi for proteolytic activation. The SCAP antibody provides an essential tool for studying the molecular regulation of lipid metabolism and cholesterol signaling.SREBP cleavage-activating protein contains multiple transmembrane domains and a sterol-sensing domain that binds cholesterol. Under high-cholesterol conditions, SCAP associates with insulin-induced gene (INSIG) proteins in the ER, retaining SREBPs in an inactive state. When sterol levels fall, this interaction is disrupted, allowing SCAP-SREBP complexes to move to the Golgi. There, site-1 and site-2 proteases release the active SREBP transcription factor, which then migrates to the nucleus to induce lipid metabolism genes. The SCAP antibody enables researchers to track this dynamic process, quantifying SCAP expression and subcellular localization under various lipid conditions.As a central regulator of lipid homeostasis, SREBP cleavage-activating protein plays critical roles in energy balance, membrane synthesis, and metabolic adaptation. Dysregulation of SCAP contributes to disorders such as hyperlipidemia, fatty liver disease, obesity, and atherosclerosis. The SCAP antibody supports investigation of these metabolic conditions by detecting protein expression in liver, adipose tissue, and other lipid-synthesizing organs. In cellular studies, it aids analysis of sterol-dependent trafficking and SREBP activation using immunoblotting and immunofluorescence techniques.In addition to cholesterol regulation, SCAP participates in broader metabolic pathways influenced by insulin signaling and nutrient status. Altered SCAP activity has been linked to metabolic reprogramming in cancer cells, where enhanced lipid biosynthesis supports rapid proliferation. The SCAP antibody can be used to study these mechanisms and assess the impact of pharmacologic SCAP inhibition on lipid synthesis and growth control. Western blotting and immunohistochemistry using this antibody reveal SCAP's distribution across the ER and Golgi, providing a spatial understanding of its sterol-sensing function.NSJ Bioreagents supplies the SCAP antibody with validated specificity and consistent performance for applications in molecular biology, metabolism, and disease research. By enabling precise detection of SREBP cleavage-activating protein, this reagent supports detailed study of lipid metabolism and its regulation. The SCAP antibody remains a key tool for uncovering how sterol sensing and SREBP activation maintain lipid balance in normal physiology and metabolic disorders.